{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:51:50Z","timestamp":1781650310186,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bursa Uludag University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Biochemical recurrence (BCR) after primary treatment for prostate cancer presents a significant clinical challenge. Conventional imaging modalities have limited sensitivity for detecting sites of recurrence, particularly at low prostate specific antigen (PSA) levels. Prostate specific membrane antigen positron emission tomography\/computed tomography (PSMA PET\/CT) has emerged as a promising diagnostic tool that may transform the management paradigm for recurrent prostate cancer. To systematically evaluate the diagnostic performance of PSMA PET\/CT in patients with biochemical recurrence of prostate cancer, compare it with conventional imaging modalities, and assess its impact on salvage therapy decisions. A systematic review was conducted following the PRISMA guidelines. PubMed\/MEDLINE, Embase, Cochrane Library, and Web of Science were searched for studies published between 2020 and 2025. Studies evaluating PSMA PET\/CT in patients with biochemical recurrence after primary treatment were included. The primary outcomes were detection rates stratified by PSA levels, diagnostic accuracy compared to conventional imaging, and the impact on management decisions. PSMA PET\/CT demonstrated superior detection rates compared to conventional imaging across all PSA levels, with detection rates ranging from 36.2% to 96.7% for PSA levels below 0.5 ng\/mL and above 5 ng\/mL, respectively. In patients with negative conventional imaging, PSMA PET\/CT identified true positive lesions in 64% of cases (95% CI, 56.7%-71.5%). Among patients with high-risk biochemically recurrent prostate cancer and negative conventional imaging, PSMA PET\/CT detected distant metastatic disease (M1) in 46% of patients. Management plans were altered in 54-76% of cases based on PSMA PET\/CT findings, with significant implications for salvage therapy targeting. PSMA PET\/CT significantly outperforms conventional imaging in detecting sites of recurrence across all PSA levels, with particularly notable advantages at low PSA values. The high detection rates and accuracy of PSMA PET\/CT in patients with negative conventional imaging support its role as a replacement for or complement to standard imaging protocols, while acknowledging current limitations in availability, cost, and long-term outcome data. PSMA PET\/CT findings frequently alter management decisions, enabling more precise targeting of salvage therapies and potentially improving oncological outcomes.<\/jats:p>","DOI":"10.1007\/s12149-026-02192-2","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:47:29Z","timestamp":1776062849000},"page":"469-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA PET\/CT imaging for biochemical recurrence in prostate cancer: can it replace conventional imaging and guide salvage therapy?"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4694-5850","authenticated-orcid":false,"given":"Efrah Ahmed","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"1","key":"2192_CR1","first-page":"5","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):5\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2192_CR2","first-page":"351","volume":"83","author":"P Cornford","year":"2023","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2023 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2023;83(4):351\u201366.","journal-title":"Eur Urol"},{"issue":"1","key":"2192_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.eururo.2016.01.029","volume":"70","author":"L Evangelista","year":"2022","unstructured":"Evangelista L, Briganti A, Fanti S, et al. New clinical indications for 18F\/11C-choline, new tracers for positron emission tomography, and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol. 2022;70(1):161\u201375.","journal-title":"Eur Urol"},{"issue":"10231","key":"2192_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"4","key":"2192_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2022","unstructured":"Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [18F]DCFPyL and [68 Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2022;17(4):575\u201384.","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"2192_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2023","unstructured":"Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2023;77(4):403\u201317.","journal-title":"Eur Urol"},{"issue":"12","key":"2192_CR7","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","volume":"61","author":"WP Fendler","year":"2020","unstructured":"Fendler WP, Ferdinandus J, Czernin J, et al. Impact of68 Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med. 2020;61(12):1793\u20139.","journal-title":"J Nucl Med"},{"issue":"7","key":"2192_CR8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.2967\/jnumed.123.267271","volume":"65","author":"MT Fleming","year":"2024","unstructured":"Fleming MT, Hermsen R, Purysko AS, et al. True-positive18 F-flotufolastat lesions in patients with prostate cancer recurrence with baseline-negative conventional imaging: results from the prospective, phase 3, multicenter SPOTLIGHT study. J Nucl Med. 2024;65(7):1080\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"2192_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.52971","volume":"8","author":"A Holzgreve","year":"2025","unstructured":"Holzgreve A, Armstrong WR, Clark KJ, et al. PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw Open. 2025;8(1):e2452971.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2192_CR10","first-page":"1273","volume":"64","author":"L Wang","year":"2023","unstructured":"Wang L, Wu Z, Tian J, et al. Diagnostic performance of68 Ga-PSMA PET\/CT for detection of recurrent prostate cancer: a systematic review and meta-analysis. J Nucl Med. 2023;64(8):1273\u201382.","journal-title":"J Nucl Med"},{"issue":"11","key":"2192_CR11","first-page":"1589","volume":"8","author":"N Tan","year":"2022","unstructured":"Tan N, Bavadian N, Calais J, et al. PSMA PET\/CT vs conventional imaging for biochemical recurrence of prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2022;8(11):1589\u2013600.","journal-title":"JAMA Oncol"},{"issue":"11","key":"2192_CR12","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of18 F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. JAMA Oncol. 2021;7(11):1635\u201342.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2192_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12885-021-08026-w","volume":"21","author":"J Calais","year":"2021","unstructured":"Calais J, Czernin J, Fendler WP, et al. Randomized prospective phase III trial of68 Ga-PSMA-11 PET\/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2021;21(1):512.","journal-title":"BMC Cancer"},{"issue":"4","key":"2192_CR14","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00259-018-4203-0","volume":"46","author":"J M\u00fcller","year":"2022","unstructured":"M\u00fcller J, Ferraro DA, Muehlematter UJ, et al. Clinical impact of68 Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. Eur J Nucl Med Mol Imaging. 2022;46(4):889\u2013900.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2192_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2967\/jnumed.118.212563","volume":"60","author":"NS Schmidt-Hegemann","year":"2022","unstructured":"Schmidt-Hegemann NS, Stief C, Kim TH, et al. Outcome after PSMA PET\/CT-based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a 2-institution retrospective analysis. J Nucl Med. 2022;60(2):227\u201333.","journal-title":"J Nucl Med"},{"issue":"5","key":"2192_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650\u20139.","journal-title":"JAMA Oncol"},{"issue":"8","key":"2192_CR17","first-page":"2768","volume":"49","author":"LG Gordon","year":"2022","unstructured":"Gordon LG, Elliott TM, Joshi A, et al. Cost-effectiveness analysis of PSMA PET\/CT for the detection of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(8):2768\u201378.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2192_CR18","first-page":"78","volume":"9","author":"S Tran","year":"2023","unstructured":"Tran S, Jambor I, Sepp\u00e4nen M, et al. Economic evaluation of prostate-specific membrane antigen positron emission tomography\/computed tomography for prostate cancer restaging: a systematic review. Eur Urol Focus. 2023;9(1):78\u201385.","journal-title":"Eur Urol Focus"},{"issue":"3","key":"2192_CR19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines\u00ae insights: Prostate cancer, version 3.2024. J Natl Compr Canc Netw. 2024;22(3):140\u201350.","journal-title":"J Natl Compr Canc Netw"},{"key":"2192_CR20","unstructured":"European Association of Urology. Prostate Cancer Guidelines 2023: Summary of changes. Accessed March 2025. Available from: https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"issue":"3","key":"2192_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2021","unstructured":"Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2021;59(3):469\u201378.","journal-title":"J Nucl Med"},{"issue":"4","key":"2192_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","volume":"73","author":"SP Rowe","year":"2022","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies. Eur Urol. 2022;73(4):485\u20137.","journal-title":"Eur Urol"},{"key":"2192_CR23","doi-asserted-by":"crossref","unstructured":"Calais J, Czernin J, Cao M, et al. 68 Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0\u00a0ng\/mL: impact on salvage radiotherapy planning. J Nucl Med. 2021;59(2):230-237.","DOI":"10.2967\/jnumed.117.201749"},{"issue":"12","key":"2192_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"6","key":"2192_CR25","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2021","unstructured":"Fendler WP, Calais J, Eiber M, et al. Assessment of68 Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2021;5(6):856\u201363.","journal-title":"JAMA Oncol"},{"issue":"6","key":"2192_CR26","doi-asserted-by":"publisher","first-page":"866","DOI":"10.2967\/jnumed.119.235028","volume":"61","author":"L Emmett","year":"2023","unstructured":"Emmett L, Tang R, Nandurkar R, et al. 3-Year freedom from progression after68 Ga-PSMA PET\/CT-triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial. J Nucl Med. 2023;61(6):866\u201372.","journal-title":"J Nucl Med"},{"issue":"1","key":"2192_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2022","unstructured":"Roach PJ, Francis R, Emmett L, et al. The impact of68 Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med. 2022;59(1):82\u20138.","journal-title":"J Nucl Med"},{"key":"2192_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3746","author":"C Belliveau","year":"2025","unstructured":"Belliveau C, Saad F, Duplan D, et al. Prostate-specific membrane antigen PET-guided intensification of salvage radiotherapy after radical prostatectomy: a Phase 2 randomized clinical trial. JAMA Oncol. 2025. https:\/\/doi.org\/10.1001\/jamaoncol.2025.3746.","journal-title":"JAMA Oncol"},{"issue":"2","key":"2192_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.euf.2020.12.009","volume":"7","author":"J Calais","year":"2021","unstructured":"Calais J, Armstrong WR, Kishan AU, et al. Update from PSMA-SRT trial NCT03582774: a randomized phase 3 imaging trial of prostate-specific membrane antigen positron emission tomography for salvage radiation therapy for prostate cancer recurrence powered for clinical outcome. Eur Urol Focus. 2021;7(2):238\u201340. https:\/\/doi.org\/10.1016\/j.euf.2020.12.009.","journal-title":"Eur Urol Focus"},{"issue":"8","key":"2192_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081118","volume":"11","author":"E Jussing","year":"2021","unstructured":"Jussing E, Milton S, Sam\u00e9n E, et al. Clinically applicable cyclotron-produced Gallium-68 gives high-yield radiolabeling of DOTA-based tracers. Biomolecules. 2021;11(8):1118.","journal-title":"Biomolecules"},{"key":"2192_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2021.109825","volume":"176","author":"J Siikanen","year":"2021","unstructured":"Siikanen J, Jussing E, Milton S, et al. Cyclotron-produced68 Ga from enriched68 Zn foils. Appl Radiat Isot. 2021;176:109825.","journal-title":"Appl Radiat Isot"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02192-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:54:54Z","timestamp":1781646894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02192-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2192"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02192-2","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no conflicts of interest related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This systematic review did not involve human subjects research and therefore did not require approval from an Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}